Positive News SentimentPositive NewsNASDAQ:AXGN AxoGen (AXGN) Stock Forecast, Price & News $8.89 -0.02 (-0.22%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$8.77▼$9.0650-Day Range$8.48▼$10.3852-Week Range$7.20▼$13.66Volume80,900 shsAverage Volume215,693 shsMarket Capitalization$380.49 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AxoGen MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.2% Upside$17.00 Price TargetShort InterestHealthy1.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.54Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.64) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector344th out of 1,010 stocksElectromedical Equipment Industry10th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, AxoGen has a forecasted upside of 91.2% from its current price of $8.89.Amount of Analyst CoverageAxoGen has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.96% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AxoGen has recently decreased by 4.78%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 3.1 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AxoGen this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.51% of the stock of AxoGen is held by insiders.Percentage Held by Institutions76.22% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.64) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -15.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -15.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AxoGen (NASDAQ:AXGN) StockAxogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.Read More Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address AXGN Stock News HeadlinesMay 24, 2023 | finance.yahoo.comAxogen to Participate at Jefferies Healthcare ConferenceMay 20, 2023 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Coverage Initiated by Analysts at StockNews.comMay 29, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 17, 2023 | americanbankingnews.comBrokers Set Expectations for AxoGen, Inc.'s FY2023 Earnings (NASDAQ:AXGN)May 12, 2023 | finance.yahoo.comAxogen to Participate at JMP Securities Life Sciences ConferenceMay 10, 2023 | msn.comAxoGen GAAP EPS of -$0.10 beats by $0.12, revenue of $36.7M beats by $1.24MMay 10, 2023 | finance.yahoo.comAxogen, Inc. Reports 2023 First Quarter Financial ResultsMay 10, 2023 | msn.comAxoGen Q1 2023 Earnings PreviewMay 29, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 8, 2023 | americanbankingnews.comAxoGen (AXGN) to Release Quarterly Earnings on TuesdayApril 27, 2023 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Stock Rating Upgraded by StockNews.comApril 18, 2023 | finance.yahoo.comAxogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023April 18, 2023 | finance.yahoo.comEven With A 26% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance CompletelyApril 2, 2023 | americanbankingnews.comShort Interest in AxoGen, Inc. (NASDAQ:AXGN) Expands By 19.3%March 31, 2023 | americanbankingnews.comAxoGen's (AXGN) Buy Rating Reiterated at Canaccord Genuity GroupMarch 29, 2023 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Rating Lowered to Hold at StockNews.comMarch 17, 2023 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Call TranscriptMarch 16, 2023 | finance.yahoo.comAxoGen Full Year 2022 Earnings: EPS Beats ExpectationsMarch 14, 2023 | finance.yahoo.comAxogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial ResultsMarch 10, 2023 | finance.yahoo.comAxogen, Inc. Appoints Marc Began as Executive Vice President and General CounselMarch 6, 2023 | finance.yahoo.comAxogen, Inc. Appoints Marc Began as Executive Vice President and General CounselMarch 2, 2023 | finance.yahoo.comAxogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023March 1, 2023 | finance.yahoo.comAxoGen (NASDAQ:AXGN) investors are sitting on a loss of 76% if they invested five years agoFebruary 13, 2023 | finance.yahoo.comAxogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing OfficerJanuary 9, 2023 | finance.yahoo.comAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022January 5, 2023 | finance.yahoo.comAxogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and ConduitsJanuary 4, 2023 | finance.yahoo.comAxogen to Participate at J.P. Morgan 41st Annual Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address AXGN Company Calendar Last Earnings3/14/2023Today5/29/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees428Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+91.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,950,000.00 Net Margins-17.01% Pretax Margin-17.01% Return on Equity-15.23% Return on Assets-7.88% Debt Debt-to-Equity Ratio0.68 Current Ratio4.18 Quick Ratio3.24 Sales & Book Value Annual Sales$138.58 million Price / Sales2.75 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book3.72Miscellaneous Outstanding Shares42,800,000Free Float39,586,000Market Cap$380.49 million OptionableOptionable Beta0.63 Key ExecutivesKaren L. ZaderejChairman, President & Chief Executive OfficerMike DonovanVice President-OperationsPeter J. MarianiChief Financial Officer & Executive Vice PresidentErick Wayne DeVinneyVice President-Clinical & Translational SciencesIvica DucicMedical DirectorKey CompetitorsEdap TmsNASDAQ:EDAPZynexNASDAQ:ZYXIViewRayNASDAQ:VRAYFONARNASDAQ:FONRBioSig TechnologiesNASDAQ:BSGMView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 8,039 shares on 5/18/2023Ownership: 0.075%New York State Common Retirement FundSold 11,500 shares on 5/18/2023Ownership: 0.033%Perceptive Advisors LLCBought 21,665 shares on 5/16/2023Ownership: 3.291%Squarepoint Ops LLCBought 13,240 shares on 5/16/2023Ownership: 0.074%Susquehanna International Group LLPBought 21,428 shares on 5/16/2023Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions AXGN Stock - Frequently Asked Questions Should I buy or sell AxoGen stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks. What is AxoGen's stock price forecast for 2023? 4 Wall Street analysts have issued twelve-month price targets for AxoGen's stock. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 91.2% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts. How have AXGN shares performed in 2023? AxoGen's stock was trading at $9.98 at the beginning of the year. Since then, AXGN shares have decreased by 10.9% and is now trading at $8.89. View the best growth stocks for 2023 here. When is AxoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our AXGN earnings forecast. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings results on Tuesday, March, 14th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.06. The medical equipment provider had revenue of $36.20 million for the quarter, compared to analyst estimates of $36.10 million. AxoGen had a negative net margin of 17.01% and a negative trailing twelve-month return on equity of 15.23%. What ETFs hold AxoGen's stock? ETFs with the largest weight of AxoGen (NASDAQ:AXGN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), IQ Chaikin U.S. Small Cap ETF (CSML), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI), What guidance has AxoGen issued on next quarter's earnings? AxoGen issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $156.67 million. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL). What is AxoGen's stock symbol? AxoGen trades on the NASDAQ under the ticker symbol "AXGN." Who are AxoGen's major shareholders? AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (8.54%), BlackRock Inc. (7.45%), First Light Asset Management LLC (4.53%), Bank of America Corp DE (4.17%), William Blair Investment Management LLC (3.73%) and Perceptive Advisors LLC (3.29%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AxoGen's stock price today? One share of AXGN stock can currently be purchased for approximately $8.89. How much money does AxoGen make? AxoGen (NASDAQ:AXGN) has a market capitalization of $380.49 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. How many employees does AxoGen have? The company employs 428 workers across the globe. How can I contact AxoGen? AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801. This page (NASDAQ:AXGN) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.